Mitomycin

Mitomycin is a type of chemotherapy drug used to treat cancer. It works by damaging the DNA of cancer cells, stopping them from growing and dividing. It's sometimes called Mitomycin C.

Brand names:Mutamycin
Medication

What people taking Mitomycin report

Every report comes from a Lived member, sent anonymously.

Have you tried Mitomycin for Non-Muscle Invasive Bladder Cancer?

NameHow it went

About Mitomycin

What It's For

Mitomycin, also called mitomycin C, is a chemotherapy drug used to treat several cancers. It belongs to a group called anticancer antibiotics: despite the name, it is used only to fight cancer, not infections. How it is given changes what it treats and what side effects matter, so it helps to know which form your team is recommending. Given into a vein, generic mitomycin and the brand Mutamycin are approved for advanced stomach or pancreatic cancer, in combination with other chemotherapy or when other treatments have stopped working. Doctors also commonly use it, alongside fluorouracil (5-FU) or capecitabine and radiation, as standard treatment for anal cancer, where this combination helps many people avoid surgery and a permanent colostomy. It is occasionally used for some other cancers. Mitomycin is also placed directly where a cancer sits in the urinary tract, which keeps most of the drug out of the bloodstream. Zusduri is a gel version instilled into the bladder for adults whose low-grade, intermediate-risk bladder cancer has come back without growing into the bladder muscle. Jelmyto is a related gel placed into the inner drainage area of the kidney for adults with low-grade cancer of the upper urinary tract (the kidney lining and ureter). A single dose of generic mitomycin is also often put into the bladder right after a bladder tumor is surgically removed, to lower the chance it returns. A separate product, Mitosol, is used briefly on the eye during glaucoma surgery to limit scarring; that use is not cancer treatment.

How It Works

Cancer cells divide more often than most healthy cells, and each division requires copying the cell's DNA. Mitomycin binds the two strands of DNA together (cross-linking). A cell whose DNA is tied together this way cannot copy it properly, so it stops dividing or dies. The same effect reaches other fast-dividing cells, which explains its main side effects when given into a vein: the bone marrow that makes blood cells and the lining of the mouth are especially sensitive. When mitomycin is instilled into the bladder or kidney, it acts mostly on the lining it touches. Jelmyto and Zusduri are mixed into a gel that is liquid when cold and firms up at body temperature, which keeps the drug in contact with the tumor longer before it is passed in the urine.

Dosage & Administration

Every form of mitomycin is given by a clinician in a hospital, clinic or urology office; it is never taken at home. Doses are calculated by the oncology team. Intravenous mitomycin is usually given as a single infusion every 6 to 8 weeks, or on a set day within a chemoradiation plan for anal cancer. Because its effect on blood counts builds up and appears late, the next dose waits until counts have recovered, and doses are reduced if side effects were significant. Zusduri is instilled through a thin urinary catheter once a week for six weeks. Jelmyto is given once a week for six weeks through a small tube passed up the ureter or through the back into the kidney, often with sedation or anesthesia; people who respond may continue with monthly treatments for up to 11 more. Before each Jelmyto treatment, people take sodium bicarbonate tablets by mouth to make urine less acidic. After a bladder or kidney instillation, urine may look violet to blue. For at least 6 hours after Jelmyto and 24 hours after Zusduri, sit to urinate, avoid getting urine on the skin, wash hands and the genital area afterward, and flush the toilet several times.

Side Effects

With intravenous mitomycin, the most important effect is a drop in blood counts, which happens in most people and can appear any time in the eight weeks after a dose, on average about four weeks in. Low white blood cells make infections more likely and more dangerous, and low platelets make bleeding easier. Call the care team right away for a fever, chills, sore throat or other signs of infection, or for unusual bleeding or bruising. Other common effects include nausea, vomiting, loss of appetite, mouth sores, hair loss and tiredness. If mitomycin leaks out of the vein during an infusion, it can badly damage the skin and tissue around it, and redness or sores can appear weeks or months later. Report pain, burning, swelling or a sore near the IV site. Less often, intravenous mitomycin harms the kidneys or lungs. A rare but serious problem called hemolytic uremic syndrome destroys red blood cells and can cause lasting kidney failure, mostly after larger total doses. Contact the team promptly for passing much less urine, new swelling of the face, hands or legs, bloody stools, or unusual weakness. New shortness of breath or a dry cough also needs prompt assessment, and severe trouble breathing is an emergency. Bladder and kidney instillations mainly cause urinary symptoms: burning or painful urination, needing to urinate often, blood in the urine and urinary tract infections. With Jelmyto, narrowing of the ureter is very common (more than half of people in the main study), which can back urine up into the kidney. Flank pain, fever or a change in kidney tests should be reported promptly; a small tube called a stent is often placed to keep urine draining.

Interactions & Warnings

Intravenous mitomycin is not given to people with low platelets or a bleeding disorder, and is generally avoided when kidney function is significantly reduced. Bladder and kidney gels are not used if there is a hole or tear in the bladder or urinary tract, because the drug could then reach the bloodstream and cause serious harm. Anyone who has had an allergic reaction to mitomycin should not receive it again. Mitomycin adds to the blood-count effects of other chemotherapy, so combined regimens are dosed with this in mind. Severe breathing problems have occurred when vinca alkaloids (chemotherapy drugs such as vinorelbine or vinblastine) were given to people who had received mitomycin. Tell the team about all medicines, supplements and recent treatments. Mitomycin can harm a developing baby. People who could become pregnant are advised to use effective contraception during treatment and for 6 months after the last dose, and those with a partner who could become pregnant for 3 months. Breastfeeding is avoided during treatment and for at least a week after the final dose.

What to Expect

For intravenous mitomycin, much of treatment revolves around blood tests: counts are checked before each dose and for at least eight weeks after the last one, because the drop can arrive late and the effect builds over repeated courses. Kidney function is also tracked. Your team will judge benefit with scans or exams over the course of treatment rather than right away. For anal cancer, mitomycin is part of a defined chemoradiation course of several weeks, and response is assessed in the months that follow. With bladder or kidney instillations, each visit takes a short procedure and some time holding the medicine, and burning or frequent urination can follow. Response is checked about three months after starting, by looking inside the bladder or kidney with a scope and testing urine. In the studies behind approval, about 78% of people treated with Zusduri and 58% with Jelmyto had no visible cancer at that check, and most who responded remained clear a year later. These studies did not compare mitomycin with other treatments, and low-grade urinary tract cancers often recur, so regular scope checks continue long after treatment ends.

Questions to Ask Your Doctor

  1. 1.Which form of mitomycin are you recommending for me, and why that one instead of surgery or another treatment?
  2. 2.How will we know whether it is working, and when is the first check?
  3. 3.Which blood or kidney tests will I need, and how will results change my next dose?
  4. 4.What symptoms should make me call you right away, and how do I reach the team after hours?
  5. 5.What should I know about contraception, pregnancy or fertility before I start?

Last reviewed • Oct 2026

Educational content, not medical advice.